- Entellus Medical (NASDAQ:ENTL) initiated with Outperform rating by William Blair.
- Lion Biotech (LBIO) initiated with Buy rating and $13 (114% upside) price target by Rodman & Renshaw.
- Intersect ENT (NASDAQ:XENT) initiated with Outperform rating by William Blair.
- Insulet (NASDAQ:PODD) upgraded to Buy with a $47 (18% upside) price target by BTIG Research.
- Depomed (DEPO) upgraded to Neutral with a $10 (9% downside risk) price target by Piper Jaffray.
- Insys Therapeutics (NASDAQ:INSY) downgraded to Neutral with a $10 (15% downside risk) price target by Piper Jaffray.
- Source: Bloomberg